For the roughly 38 million Americans living with diabetes, and the hundreds of millions more with prediabetes or metabolic risk, the most useful piece of medical hardware of the last decade has been the continuous glucose monitor. A small adhesive sensor that reads interstitial glucose every few minutes has reshaped how endocrinologists titrate insulin and how patients eat, sleep, and exercise. The catch is price. Even after Dexcom's Stelo and Abbott's Lingo received FDA clearance in 2024 for over-the-counter use in adults not on insulin, a month of sensors still runs roughly $89 to $99 out of pocket, and prescription CGMs without insurance coverage can cost several hundred dollars a month. That gap is the opening that One Health Biosensing, a New York pre-seed company founded in 2024 by Jeffrey Dachis, says it intends to close [One Health Biosensing, 2024].
The patient population Dachis is naming is explicit: people with type 2 diabetes, prediabetes, and metabolic disease who are priced out of the current CGM market, including in lower-income geographies where reimbursement does not exist at all. The company's public pitch is a next-generation CGM "built and priced to be accessible and affordable on day one," with an ambition to extend the same biosensor chemistry into animal and environmental diagnostics [One Health Biosensing, 2024] [Crunchbase, 2024]. The standard of care today, for a newly diagnosed type 2 patient in the United States, is typically metformin, fingerstick glucose checks, an A1C test every three to six months, and lifestyle counseling, with CGM increasingly added for those on insulin or struggling to reach glycemic targets. CGM access for the much larger non-insulin population remains uneven and largely cash-pay.
The bet
The wedge One Health Biosensing is describing is hardware economics. The company says its sensor is engineered for ultra-low cost manufacturing and pairs with AI-enabled software for glucose forecasting, claims that sit at the company's own description level and have not been independently reviewed [Wefunder, 2024]. The intellectual property story is more concrete. Kingscrowd reports more than 50 issued patents associated with the company [Kingscrowd, 2024], and Google Patents lists European Patent EP3977480A1, covering systems for biomonitoring and blood glucose forecasting, originally assigned to Informed Data Systems Inc, doing business as One Drop, the prior Dachis company [Google Patents, 2026]. That lineage matters: the patent estate appears to carry forward work already done at One Drop on glucose prediction models, which is rare for a company at this stage.
| Milestone | Detail | Source |
|---|---|---|
| Founded | February 2024, New York | [Kingscrowd, 2024] |
| Funding stage | Pre-seed, Wefunder community round, $50,000 minimum target | [Kingscrowd, 2024] |
| Patent portfolio | More than 50 issued patents | [Kingscrowd, 2024] |
| Anchor IP | EP3977480A1, biomonitoring and glucose forecasting | [Google Patents, 2026] |
Why the category is moving
CGM is one of the few categories in digital health where unit economics, clinical evidence, and consumer demand are all moving in the same direction at once. The 2024 OTC clearances from the FDA for Dexcom's Stelo and Abbott's Lingo opened a non-prescription market for adults not on insulin, a population that dwarfs the insulin-dependent base. Payers, including Medicare, have steadily expanded coverage for type 2 patients on basal insulin. If a new entrant can credibly cut the per-sensor cost while clearing FDA review, the addressable market extends well beyond the United States into markets where current CGMs are simply unaffordable. That is the size of the prize One Health Biosensing is pointing at, and it is the reason a hardware-plus-software bet at this stage is not unreasonable, even though the regulatory road is long.
The team and the traction
Jeffrey Dachis is the named founder and, per Crunchbase, founder and CEO of One Health Biosensing [Crunchbase, 2024]. He previously founded, chaired, and led One Drop, the diabetes management company whose patent estate appears to underpin the new venture, and he co-founded Razorfish, the digital agency he led as CEO during the first internet wave [Crunchbase, 2024] [TechCrunch, 2013]. He later founded Dachis Group, a social analytics company, and has held roles at Sprinklr and Bond Art & Science [TechCrunch, 2010] [RocketReach, 2026]. The Wefunder page references more than $5 billion in cumulative exits across the broader founding team's prior companies, including Razorfish, One Drop, Big Foot, and Welldoc, a figure disclosed by the company in its raise materials [Wefunder, 2024]. Current traction is early: a community round on Wefunder with a $50,000 minimum target, no disclosed institutional lead, and no publicly named pilot customers or clinical sites [Kingscrowd, 2024].
The honest counterfactual
The bear case is straightforward. Dexcom and Abbott together control the CGM market, both have OTC products on shelves, both have manufacturing scale measured in tens of millions of sensors per year, and both have clinical trial infrastructure that a pre-seed company cannot match. Any new CGM in the United States will need either a 510(k) clearance against a predicate or a de novo pathway, and accuracy, measured as MARD against venous reference, is the metric that decides whether clinicians will write for it. The bull answer, grounded in what the cited evidence supports, is that Dachis is not starting from zero on either chemistry or algorithms: the patent estate, including EP3977480A1, originated inside a company he previously ran, which collapses some of the usual early-stage scientific risk [Google Patents, 2026]. Whether that translates into a sensor that performs at parity with Dexcom G7 or FreeStyle Libre 3 at a fraction of the cost is the empirical question that the next two years of bench data and clinical work will answer.
What to watch
The near-term milestones that will tell readers whether this thesis is real are concrete. First, an institutional seed round with a named life-sciences lead would signal that diligence on the IP and the sensor design held up. Second, any disclosure of an FDA pre-submission meeting, a pilot clinical accuracy study, or a published MARD figure would move the story from pitch to evidence. Third, a manufacturing partner or contract sensor fab announcement would speak to the cost claim, which is ultimately the entire premise. None of those are guaranteed, but they are the right things to look for, and they are the things that will determine whether patients with type 2 diabetes who currently cannot afford a CGM ever get to wear one made by this company.
Pulse Raman, Health and Bio Correspondent